


Journal Pre-proof

Safety use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center

Lucie Pothén, Halil Yildiz, Julien De Greef, Andrea Penaloza, Christophe Beauloye, Leila Belkhir, Jean Cyr Yombi



PII: S1477-8939(20)30278-7

DOI: <https://doi.org/10.1016/j.tmaid.2020.101788>

Reference: TMAID 101788

To appear in: *Travel Medicine and Infectious Disease*

Received Date: 5 May 2020

Revised Date: 5 June 2020

Accepted Date: 10 June 2020

Please cite this article as: Pothén L, Yildiz H, De Greef J, Penaloza A, Beauloye C, Belkhir L, Yombi JC, Safety use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center, *Travel Medicine and Infectious Disease* (2020), doi: <https://doi.org/10.1016/j.tmaid.2020.101788>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Ltd.

Safety use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: clinical experience in a Belgian tertiary center.

Lucie Pothen M.D ¹; Halil Yildiz M.D ¹; Julien De Greef M.D ¹; Andrea Penaloza M.D, PhD²,
Christophe Beauloye M.D, PhD³; Leila Belkhir M.D, PhD ¹, Jean Cyr Yombi M.D ¹

¹Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium

² Department of Emergency Medicine, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium

³ Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussel, Belgium

Corresponding author:

Lucie Pothen, M.D

Department of Internal Medicine and Infectious Diseases

Cliniques Universitaires Saint-Luc

Université Catholique de Louvain

Brussels

Belgium

lucie.pothen@uclouvain.be

Word count: 522

Conflict of interest: The authors declare that they have no conflicts of interest.

Dear Editor,

Based on studies showing in vitro antiviral activity of chloroquine (CQ) and hydroxychloroquine (HCQ) on SARS-CoV-2 (1), Belgian COVID interim guidelines rapidly (March 13th, 2020) recommended treating hospitalized patients suffering from severe COVID-19 with HCQ, 400 mg bid the first day followed by 200 mg bid for 4 additional days (for GFR > 30 ml/min).

Despite some encouraging preliminary clinical data (2,3), major concerns have been raised about the use of HCQ to treat COVID-19 (5), particularly regarding potential cardiac toxicity (i.e. QTc increase and risk of *torsade de pointe*). Because HCQ has been safely used for many years for various indications (e.a. connective tissue diseases) (6), we decided to follow interim Belgian guidance for all eligible patients hospitalized in our COVID-19 wards. Moreover, we decided to add azithromycin (AZM), 500 mg Id for 3 days, for selected patients, based on our knowledge of its antibiotic, immunomodulatory and possible antiviral actions (3).

Between March 8 and April 15, 2020, a total of 114 patients with confirmed COVID-19 pneumonia were hospitalized in our dedicated units. Patient characteristics are summarized in the Table 1. The mean age was 63 years and men represented 55.3%. A vast majority (n=104) presented with severe disease and half (n=59) had cardiovascular disease history. Other comorbidities are listed in the Table 1. HCQ was administered to 107 patients after QTc evaluation by electrocardiogram (ECG). HCQ was avoided in patients under palliative care (n=4), if QTc was over 500 msec (n=1), and if patients had received prior treatment with CQ (n=2). Mean initial QTc was 429 msec (Bazett formula used for correction). Biochemistry was followed on a regular basis, and ionic disturbances (hypokalemia, hypomagnesemia)

were treated by supplementation if present. Repeat ECG was not systematically performed during HCQ treatment, except in case of drug-drug interaction which could potentially increase QTc (see foot note of Table1). The main drug-drug interaction was driven by addition of AZM (n=28). In this group, QTc was controlled at day 2 of combination therapy (n=24). We observed a significant increase in mean QTc, from 418 to 433 msec ($p < 0,01$ with paired t-test), but none of the patients showed a QTc over 500 msec.

Furthermore, in our entire cohort there were no sudden deaths nor syncope requiring resuscitation or ICU admission. All ICU admissions (n=13) were linked to respiratory failure resulting from COVID-19 pneumonia. One patient on HCQ presented AV nodal reentry tachycardia in parallel with respiratory failure, and was successfully treated with adenosine. All deaths in our cohort (n= 12) were attributed to COVID-19 infection.

In conclusion, based on our clinical experience, no safety issues were encountered with the use of HCQ for the treatment of COVID-19. In coherence with recent data published here (7), its association with AZM also seems to be safe, despite a significant increase of QTc that should be carefully monitored. The efficacy of HCQ and its combination with azithromycin on COVID-19 infection needs, of course, to be strengthened with further evidence from large randomized clinical trials. However, at this point of the COVID-19 pandemic, we find it relevant to share our clinical experience with this well-known, readily available compound (HCQ) which has limited contraindications and may help in the fight against this outbreak.

Table 1. Characteristics of patients.

No. Patients	114
Age, mean [range], years	63 [19-95]
Sex	
Male (%)	63 (55.3)
Female (%)	51 (44.7)
Patients with comorbidities (%)	
None	29 (25,4%)
Cardiovascular disease	59 (51,8%)
Hypertension	56 (49,1%)
COPD	17 (14,9%)
Diabetes	25 (21,9%)
Immunosuppression	17 (14,9%)
O ² sat. on admission. while breathing ambient air, mean [range], %	90,1 [55-99]
Clinical presentation * (%)	
Mild disease	0 (0%)
Moderate disease	10 (8,8%)
Severe disease	104 (91,2%)
HCQ (%)	107 (93.8)
ECG pretreatment (% of HCQ)	100 (93.4)
QTc initial, mean [range] msec	429 [342-493]
Drug-drug interaction (% of HCQ)	34 (31.8)
Azithromycin	28 (26.2)
Other **	6 (5.6)
ECG CTRL at day 2 (% of patient w. drug-drug interaction)	27 (79.4)
Azithromycin	24 (70.5)
Other	3 (8.8)

**"mild disease" was define as symptoms of upper respiratory infection (fever, fatigue, myalgia, cough, sore throat, runny nose, sneezing) or digestive symptoms (nausea, vomiting, abdominal pain, diarrhea); "moderate" as clinical (fever and cough) and radiological pneumonia (infiltrates) without hypoxemia; "severe" as clinical and radiological pneumonia with hypoxemia (O² saturation < 93%).

**other consisted in escitalopram, citalopram, fluconazole, valproate, mirtazapine and olanzapine.

References

1. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis* 2020 March 9. doi:10.1093/cid/ciaa237. Epub ahead of print.
2. Z Chen, J Hu, Z Zhang, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *medRxiv* (2020) published online March 31. DOI: 10.1101/2020.03.22.20040758 (preprint).
3. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. *Travel Med Infect Dis*. 2020 Apr 11:101663. doi: 10.1016/j.tmaid.2020.101663. Online ahead of print
4. Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. *BMJ*. 2020 Apr 8;369:m1432. doi: 10.1136/bmj.m1432.
5. McGhie TK, Harvey P, Su J, Anderson N, Tomlinson G, Touma Z. Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus. *Clin Exp Rheumatol*. 2018 Jul-Aug;36(4):545-551. Epub 2018 Apr 13.
6. Million M, Lagier JC, Gautret P, Colson P, Fournier PE et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. *Travel Med Infect Dis*. 2020 May 5:101738. doi: 10.1016/j.tmaid.2020.101738.



Travel Medicine and Infectious Disease

Conflict of Interest Policy

Manuscript number (if applicable):
Article Title: safety use of HCQ.

Author name: Lucie Pothen

Declarations

Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

Conflict of Interest

A conflicting interest exists when professional judgement concerning a primary interest (such as patient's welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any competing interests

/

Funding Source

All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated.

Please state any sources of funding for your research

/

Signature (a scanned signature is acceptable, but each author must sign)

Print name

Lucie Pothen



Travel Medicine and Infectious Disease

Conflict of Interest Policy

Manuscript number (if applicable):

Article Title: *Safety Use of hydroxychlor.*

Author name:

Halil Yildiz

Declarations

Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

Conflict of Interest

A conflicting interest exists when professional judgement concerning a primary interest (such as patient's welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any competing interests

Funding Source

All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated.


Please state any sources of funding for your research

Signature (a scanned signature is acceptable, but each author must sign)

[Handwritten signature]

Print name

YILDIZ HALIL



Travel Medicine and Infectious Disease

Conflict of Interest Policy

Manuscript number (if applicable):

Article Title:

Safety use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak:

Author name:

Julien De Greef

Declarations

Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

Conflict of Interest

A conflicting interest exists when professional judgement concerning a primary interest (such as patient's welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any competing interests

No competing interests

Funding Source

All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated.

Please state any sources of funding for your research

NA

Signature (a scanned signature is acceptable, but each author must sign)

Print name

DE GREEF



Travel Medicine and Infectious Disease

Conflict of Interest Policy

Manuscript number (if applicable):
Article Title: Safety use of hydroxychloroquine
and its combination with azithromycin in the
context of Sars-CoV-2 outbreak: clinical
experience in a Belgian tertiary center

Author name: Andrea Penaloza

ations

Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

Conflict of Interest

A conflicting interest exists when professional judgement concerning a primary interest (such as patient's welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any competing interests

/ NA

Funding Source

All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated.

Please state any sources of funding for your research

/ NA.

Signature (a scanned signature is acceptable,
but each author must sign)

Print name

ANDREA PENALOZA

05/05/20



Travel Medicine and Infectious Disease

Conflict of Interest Policy

Manuscript number (if applicable):
Article Title:
Safety use of hydroxychloroquine and its combination with
azithromycin in the context of Sars-CoV-2 outbreak: clinical
experience in a Belgian tertiary center.

Author name: Beauloye

Declarations

Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

Conflict of Interest

A conflicting interest exists when professional judgement concerning a primary interest (such as patient's welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any competing interests

No conflict of interest.

Funding Source

All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated.


Please state any sources of funding for your research

Not applicable.

Signature (a scanned signature is acceptable
but each author must sign)

Print name

Beauloye



Travel Medicine and Infectious Disease

Conflict of Interest Policy

Manuscript number (if applicable):
Article Title:

Author name:

BELKHIR LEILA

Declarations

Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

Conflict of Interest

A conflicting interest exists when professional judgement concerning a primary interest (such as patient's welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any competing interests

no conflict of interest

Funding Source


All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated.

Please state any sources of funding for your research

no sources of funding

Signature (a scanned signature is acceptable, but each author must sign)

Print name

 03/05/2020

Dr. BELKHIR L.
Maladies Infectieuses
1.9336157.580
Clin. Univ St. Luc



Travel Medicine and Infectious Disease

Conflict of Interest Policy

Manuscript number (if applicable):

Article Title: *Safety Use of hydroxychl.*

Author name:

Jean-Cyr Yombi

Declarations

Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

Conflict of Interest

A conflicting interest exists when professional judgement concerning a primary interest (such as patient's welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any competing interests

/

Funding Source

All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated.

Please state any sources of funding for your research

/

Signature (a scanned signature is acceptable, but each author must sign)

[Handwritten signature]

Print name

Jean-Cyr Yombi